Appili Therapeutics to Present Progress on Tularemia Biodefense Vaccine at NATO CBRN Conference
Appili Therapeutics (OTC:APLIF) announced its participation in the NATO Chemical, Biological, Radiological and Nuclear Conference in Switzerland. Dr. Carl Gelhaus, Director of Non-Clinical Research, will present updates on ATI-1701, the company's first-in-class vaccine candidate for tularemia prevention.
The presentation will highlight preclinical data for ATI-1701, which is being developed with support from the U.S. Air Force Academy. The vaccine aims to address a critical gap in NATO's biodefense capabilities against Francisella tularensis, a highly infectious pathogen considered a top-priority biothreat. Currently, NATO forces lack specialized tularemia vaccines that are available to adversarial militaries.
Appili Therapeutics (OTC:APLIF) ha annunciato la partecipazione alla conferenza NATO su Chimica, Biologia, Radiologia e Nucleare in Svizzera. Dr. Carl Gelhaus, direttore della ricerca non clinica, presenterà aggiornamenti su ATI-1701, il candidato vaccino di prima classe dell'azienda per la prevenzione della tularemia.
La presentazione metterà in luce i dati preclinici su ATI-1701, sviluppato con il supporto della U.S. Air Force Academy. Il vaccino punta a colmare una lacuna critica nelle capacità di biodefesa della NATO contro Francisella tularensis, un agente altamente infettivo considerato una minaccia biologica di massima priorità. Attualmente le forze NATO non dispongono di vaccini specifici contro la tularemia disponibili per forze avversarie.
Appili Therapeutics (OTC:APLIF) anunció su participación en la Conferencia de Amenazas Químicas, Biológicas, Radiológicas y Nucleares de la OTAN en Suiza. Dr. Carl Gelhaus, director de Investigación No Clínica, presentará novedades sobre ATI-1701, el candidato vacunal de primera clase de la compañía para la prevención de la tularemia.
La presentación destacará los datos preclínicos de ATI-1701, desarrollado con el apoyo de la U.S. Air Force Academy. La vacuna busca cubrir una brecha crítica en las capacidades de biodefensa de la OTAN frente a Francisella tularensis, un patógeno altamente contagioso considerado una amenaza biológica prioritaria. Actualmente, las fuerzas de la OTAN carecen de vacunas especializadas contra la tularemia disponibles para ejércitos adversarios.
Appili Therapeutics (OTC:APLIF)는 스위스에서 열리는 NATO 화학·생물·방사선·핵 회의에 참여한다고 발표했습니다. 비임상연구 책임자인 Dr. Carl Gelhaus가 털라렘 예방을 위한 회사의 퍼스트인클래스 백신 후보인 ATI-1701에 대한 최신 정보를 발표합니다.
이번 발표에서는 U.S. Air Force Academy의 지원으로 개발 중인 ATI-1701의 전임상 데이터를 중점적으로 다룹니다. 이 백신은 고도로 전염성이 강한 병원체인 Francisella tularensis에 대한 NATO의 생물방어 역량에 존재하는 심각한 공백을 해결하는 것을 목표로 합니다. 현재 NATO군에는 적대 세력에 제공되는 특수 털라렘 백신이 없습니다.
Appili Therapeutics (OTC:APLIF) a annoncé sa participation à la conférence OTAN sur les menaces chimiques, biologiques, radiologiques et nucléaires en Suisse. Dr. Carl Gelhaus, directeur de la recherche non clinique, présentera des mises à jour sur ATI-1701, le candidat vaccin de premier rang de la société pour la prévention de la tularémie.
La présentation mettra en avant les données précliniques d'ATI-1701, développé avec le soutien de la U.S. Air Force Academy. Le vaccin vise à combler une lacune critique dans les capacités de biodefense de l'OTAN contre Francisella tularensis, un agent hautement infectieux considéré comme une menace biologique prioritaire. À ce jour, les forces de l'OTAN ne disposent pas de vaccins spécialisés contre la tularémie comparables à ceux disponibles pour des forces adverses.
Appili Therapeutics (OTC:APLIF) gab seine Teilnahme an der NATO-Konferenz zu Chemischen, Biologischen, Radiologischen und Nuklearen Bedrohungen in der Schweiz bekannt. Dr. Carl Gelhaus, Direktor der nicht-klinischen Forschung, wird Updates zu ATI-1701 vorstellen, dem First-in-Class-Impfkandidaten des Unternehmens zur Vorbeugung von Tularämie.
Die Präsentation wird präklinische Daten zu ATI-1701 hervorheben, das mit Unterstützung der U.S. Air Force Academy entwickelt wird. Der Impfstoff zielt darauf ab, eine kritische Lücke in den Biodefense-Fähigkeiten der NATO gegen Francisella tularensis zu schließen, einen hochinfektiösen Erreger, der als vorrangige biologische Bedrohung gilt. Derzeit fehlen den NATO-Streitkräften spezialisierte Tularämie-Impfstoffe, wie sie gegnerische Streitkräfte haben könnten.
- None.
- None.
Appili Non-Clinical Director to join NATO and allied representatives and present ATI-1701 biodefense vaccine as a potential solution to the tularemia threat
HALIFAX, Nova Scotia, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that Carl Gelhaus, Ph.D., Director of Non-Clinical Research, will participate in the NATO Chemical, Biological, Radiological and Nuclear (“CBRN”) Conference, taking place September 8–10, 2025, in Switzerland.
Dr. Gelhaus will join NATO and allied representatives and present an update on Appili’s biodefense vaccine program, highlighting ATI-1701, the company’s potential first-in-class vaccine candidate designed to prevent infection by Francisella tularensis, the causative agent of tularemia. The presentation will offer an in-depth overview of the tularemia threat to military and civilian populations and underscore the potential of ATI-1701 to address this critical gap in biodefense preparedness.
“Tularemia remains a significant biological threat to NATO and allied forces, with adversarial militaries having access to specialized tularemia vaccines that NATO currently lacks. This strategic gap underscores an urgent need for enhanced protective measures and vaccine development within NATO operations,” said Appili’s Dr. Gelhaus. “We are encouraged by the strong support from the U.S. Air Force Academy (“USAFA”) for ATI-1701 and remain dedicated to advancing this critical vaccine candidate in collaboration with government agencies, with the goal of making ATI-1701 the first U.S. FDA-approved vaccine for the prevention of tularemia.”
The presentation will highlight preclinical data and ongoing development of ATI-1701, which has been supported in part by a cooperative agreement award from the USAFA.
Francisella tularensis is a highly infectious pathogen capable of causing severe illness and death and is designated a top-priority biothreat. Medical countermeasures against this agent remain a key biodefense priority for the United States and governments around the world.
Presentation details are as follows:
Title: ATI-1701, a Live Attenuated Tularemia Vaccine: Applications for the Warfighter
Date: September 9, 2025
Time: 5:35 PM Central European Summer Time
Dr. Gelhaus will also be conducting in-person meetings throughout the conference. To request a meeting, please contact the Company at info@appilitherapeutics.com.
About ATI-1701
ATI-1701 is a novel, live-attenuated vaccine for F. tularensis, a Category A pathogen which causes tularemia. F. tularensis can be aerosolized and is over 1,000 times more infectious than anthrax. Since it is a highly infectious pathogen capable of causing severe illness, medical countermeasures for F. tularensis are a top biodefense priority for the United States and governments around the world. There is currently no approved vaccine for the prevention of tularemia in the United States or other major global markets.
About Appili Therapeutics
Appili Therapeutics is a biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including an FDA-approved ready-made suspension of metronidazole for the treatment of antimicrobial resistant infections, a vaccine candidate to prevent tularemia, a serious biological weapon threat, and a topical antiparasitic for the treatment of cutaneous leishmaniasis, a disfiguring disease. Led by a proven management team, Appili is at the center of the global fight against infection. For more information, visit www.AppiliTherapeutics.com
Media Contact:
Jenna McNeil, Communications Manager
Appili Therapeutics
E: JMcNeil@AppiliTherapeutics.com
Investor Relations Contact:
Don Cilla, President and CEO
Appili Therapeutics
E: Info@AppiliTherapeutics.com
FAQ
When is Appili Therapeutics (APLIF) presenting at the NATO CBRN Conference?
What is ATI-1701 and what is it designed for?
Who is supporting Appili's ATI-1701 vaccine development?
Why is Appili's tularemia vaccine important for NATO?
What is the current status of ATI-1701's development?
